Trial Profile
Phase 2 study of sorafenib plus protracted temozolomide in recurrent glioblastoma multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 15 Feb 2013 Actual end date changed from Sep 2010 to Dec 2010 as reported by ClinicalTrials.gov.
- 10 Jan 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 10 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.